India Ratings Boosts Viyash Scientific's Credit Profile

Viyash Scientific Limited's bank loan facilities, valued at INR 350 million, have received a significant credit rating upgrade from India Ratings. The long-term rating is now 'IND AA-' with a Stable Outlook, an improvement from the previous 'IND A' rating with a positive outlook. The short-term rating has also been raised to 'IND A1+' from 'IND A1'.

Key Rating Changes and Their Significance

The upgrade, announced on April 30, 2026, reflects India Ratings' assessment of Viyash Scientific's enhanced creditworthiness. An 'IND AA-' rating signifies a high degree of safety regarding the company's ability to meet its financial obligations. This improved standing is expected to grant Viyash Scientific access to more favorable borrowing terms, potentially lowering interest costs and enhancing its financial credibility with lenders and investors. The rated facilities total INR 350 million.

Recent Company Developments and Financial Performance

Viyash Scientific Limited, formerly Sequent Scientific Limited until its name change in January 2026, recently completed a merger with Viyash Life Sciences. This upgrade follows an 'IND A' (positive) rating assigned in January 2025. The company's financial performance has been robust, with Q3 FY26 reporting revenue growth, a 64% increase in EBITDA, and a sharp drop in Net Debt to LTM EBITDA to 0.4x. Operating margins improved to 18.9% in 9M FY2026 from 12.9% in FY2025.

Impact on Viyash Scientific and Shareholders

The rating upgrade is expected to benefit Viyash Scientific by potentially lowering finance costs, which could boost net profit. It may also facilitate easier access to larger credit lines or more favorable terms for future capital needs. This stronger credit profile enhances the company's negotiating position with financial institutions and reinforces confidence in its financial management and stability.

Potential Risks and Market Sentiment

While the rating upgrade is positive, general risks remain, including economic downturns or unforeseen events. External factors like geopolitical situations can also introduce market volatility. Additionally, in March 2026, MarketsMOJO downgraded Viyash Scientific to a 'Sell' rating due to technical indicators and mixed fundamentals, signaling potential market sentiment concerns. Data also shows an increase in working capital days from 48.7 to 70.3, suggesting potential pressure on working capital management efficiency.

Comparison with Industry Peers

The 'IND AA-' rating places Viyash Scientific within a strong credit quality bracket. While direct debt facility rating comparisons with major pharmaceutical peers like Sun Pharma, Divi's Lab, and Torrent Pharma are not consistently available, this upgrade positions Viyash Scientific favorably for accessing debt financing compared to many mid-cap companies in the sector.

Key Factors to Monitor Moving Forward

Investors should track the real impact of the upgrade on Viyash Scientific's borrowing costs and financing terms. It will also be important to observe how the company leverages its improved credit standing for future capital needs or strategic plans. Monitoring analyst recommendations, market sentiment (especially following the MarketsMOJO 'Sell' rating), and the company's ongoing financial performance, merger synergy realization, and operational efficiency will be key.